Linking APOE-ε4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology

[1]  D. Rizopoulos,et al.  Balance between innate versus adaptive immune system and the risk of dementia: a population-based cohort study , 2019, Journal of Neuroinflammation.

[2]  J. Williamson,et al.  Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial , 2019, JAMA.

[3]  John X. Morris,et al.  Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction , 2018, Nature Medicine.

[4]  D. Holtzman,et al.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight , 2018, Nature Reviews Immunology.

[5]  P. Tariot,et al.  Randomized Trial of Verubecestat for Mild‐to‐Moderate Alzheimer's Disease , 2018, The New England journal of medicine.

[6]  A. Loudon,et al.  Clocking in to immunity , 2018, Nature Reviews Immunology.

[7]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[8]  Tim Clark,et al.  Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer’s disease , 2018, Proceedings of the National Academy of Sciences.

[9]  B. Zlokovic,et al.  Alzheimer’s disease: A matter of blood–brain barrier dysfunction? , 2017, The Journal of experimental medicine.

[10]  C. Held,et al.  Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial , 2017, Journal of the American Heart Association.

[11]  A. Fagan,et al.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.

[12]  Markus Glatzel,et al.  The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. , 2017, Immunity.

[13]  W. M. Palm,et al.  Pericortical Enhancement on Delayed Postgadolinium Fluid-Attenuated Inversion Recovery Images in Normal Aging, Mild Cognitive Impairment, and Alzheimer Disease , 2017, American Journal of Neuroradiology.

[14]  D. Holtzman,et al.  Glial contributions to neurodegeneration in tauopathies , 2017, Molecular Neurodegeneration.

[15]  K. Blennow,et al.  Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype , 2017, Neurobiology of Aging.

[16]  W. M. van der Flier,et al.  Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects , 2017, Annals of neurology.

[17]  L. Collins-Praino,et al.  Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury? , 2017, Brain, Behavior, and Immunity.

[18]  S. Rose-John,et al.  The role of interleukin-6 signaling in nervous tissue. , 2016, Biochimica et biophysica acta.

[19]  B. Zlokovic,et al.  Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer’s disease , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  Sterling C. Johnson,et al.  Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation , 2015, Alzheimer's & dementia.

[21]  R. Hollingsworth,et al.  Interleukin-6 Stimulates Defective Angiogenesis. , 2015, Cancer research.

[22]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[23]  C. Iadecola,et al.  Dangerous Leaks: Blood-Brain Barrier Woes in the Aging Hippocampus , 2015, Neuron.

[24]  R. Sperling,et al.  Subjective cognitive concerns, episodic memory, and the APOE ε4 allele , 2014, Alzheimer's & Dementia.

[25]  L. Kuller,et al.  Arterial stiffness and β-amyloid progression in nondemented elderly adults. , 2014, JAMA neurology.

[26]  M. Humbert,et al.  Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscle–Like Cells in Pulmonary Hypertension , 2014, Circulation.

[27]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[28]  R. Ransohoff,et al.  Development, maintenance and disruption of the blood-brain barrier , 2013, Nature Network Boston.

[29]  C. Iadecola.  The Pathobiology of Vascular Dementia , 2013, Neuron.

[30]  M. Miller,et al.  Sample Size Requirements for Structural Equation Models , 2013, Educational and psychological measurement.

[31]  D. Blacker,et al.  The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[32]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[33]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[34]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[35]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[36]  G. Bu,et al.  Apolipoprotein E Regulates the Integrity of Tight Junctions in an Isoform-dependent Manner in an in Vitro Blood-Brain Barrier Model* , 2011, The Journal of Biological Chemistry.

[37]  G. Hansson,et al.  The immune system in atherosclerosis , 2011, Nature Immunology.

[38]  N. Herrmann,et al.  A Meta-Analysis of Cytokines in Alzheimer's Disease , 2010, Biological Psychiatry.

[39]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[40]  F. Jessen,et al.  Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. , 2010, Archives of general psychiatry.

[41]  Ilona B. Bruinsma,et al.  Apolipoprotein E protects cultured pericytes and astrocytes from D-Aβ1–40-mediated cell death , 2010, Brain Research.

[42]  J. Trojanowski,et al.  Total and phosphorylated tau protein as biological markers of Alzheimer’s disease , 2010, Experimental Gerontology.

[43]  W. Bowers,et al.  Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. , 2009, The American journal of pathology.

[44]  V. Seyfert-Margolis,et al.  Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays , 2009, BMC Immunology.

[45]  Sirkka Goebeler,et al.  Apolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age , 2009, Annals of neurology.

[46]  D. Thal,et al.  Cerebral Small Vessel Disease-Induced Apolipoprotein E Leakage Is Associated With Alzheimer Disease and the Accumulation of Amyloid &bgr;-Protein in Perivascular Astrocytes , 2008, Journal of neuropathology and experimental neurology.

[47]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[48]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[49]  T. Miida,et al.  Serum amyloid A (SAA)-induced remodeling of CSF-HDL. , 2006, Biochimica et biophysica acta.

[50]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[51]  R. Maccioni,et al.  Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. , 2004, Experimental cell research.

[52]  K. Hagihara,et al.  IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. , 2004, Biochemical and biophysical research communications.

[53]  J W Rowe,et al.  Interleukin-6 and risk of cognitive decline: MacArthur Studies of Successful Aging , 2002, Neurology.

[54]  J. Manson,et al.  Systolic and Diastolic Blood Pressure, Pulse Pressure, and Mean Arterial Pressure as Predictors of Cardiovascular Disease Risk in Men , 2000, Hypertension.

[55]  L. Bouter,et al.  Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. , 1999, The American journal of psychiatry.

[56]  Shaobo Zhang,et al.  Sample size in factor analysis. , 1999 .

[57]  S. Rose-John,et al.  Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. , 1998, Journal of immunology.

[58]  C. Duyckaerts,et al.  ApoE immunoreactivity and microglial cells in Alzheimer's disease brain , 1995, Neuroscience Letters.

[59]  J. D. L. Torre.  Impaired brain microcirculation may trigger Alzheimer's disease , 1994, Neuroscience & Biobehavioral Reviews.

[60]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Jessica L. Larson,et al.  A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains. , 2017, Journal of Alzheimer's disease : JAD.

[62]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[63]  K. Blennow,et al.  Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[64]  M. Carrillo,et al.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011 .

[65]  Hartwig Wolburg,et al.  Choroid plexus: biology and pathology , 2009, Acta Neuropathologica.

[66]  B. Muthén,et al.  TEACHER ’ S CORNER How to Use a Monte Carlo Study to Decide on Sample Size and Determine Power , 2002 .

[67]  G. Trinchieri.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. , 1995, Annual review of immunology.

[68]  K. Blennow,et al.  Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. , 1993, European neurology.

[69]  K. Blennow,et al.  Protein Analysis in Cerebrospinal Fluid , 1993 .